Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 153 No. 8 (2023)

Net survival of women diagnosed with breast tumours: a population-based study in Switzerland

  • Nena Karavasiloglou
  • Eleftheria Michalopoulou
  • Manuela Limam
  • Dimitri Korol
  • Miriam Wanner
  • Sabine Rohrmann
Cite this as:
Swiss Med Wkly. 2023;153:40087


AIMS OF THE STUDY: Although the incidence of breast carcinoma in situ has been increasing, the prognosis of breast carcinoma in situ patients has not been extensively investigated. Thus, we aimed to compare the characteristics of invasive breast tumours based on whether or not they were preceded by a breast carcinoma in situ and to estimate the 5-year net survival of patients diagnosed with different breast tumours.

METHODS: Data from women diagnosed with breast tumours between 2003 and 2016 were used in our analyses. Net survival analyses were performed using inverse probability of censoring weights (nonparametric Pohar Perme estimator). Under certain assumptions, differences in survival between the cancer population and the general population can be considered to be attributable to the cancer diagnosis (NS).

RESULTS: Descriptive observation of tumour characteristics indicated that invasive breast tumours following a breast carcinoma in situ were more frequently detected at an earlier stage and had less missing information in tumour-specific variables, compared to invasive breast tumours not preceded by a breast carcinoma in situ. Breast carcinoma in situ patients had a 5-year net survival of 1.02 (95% CI: 1.01–1.03), whereas patients diagnosed with invasive breast cancer without a recorded breast carcinoma in situ had a 5-year net survival of 0.89 (95% CI: 0.88–0.90). Patients diagnosed first with breast carcinoma in situ and then with invasive breast cancer had a 5-year net survival of 0.92 (95% CI: 0.85–1.01).

CONCLUSION: Invasive breast tumours that were preceded by a breast carcinoma in situ were detected more frequently at an earlier stage, compared to those that were not. The estimated 5-year net survival of patients with breast tumours was good.


  1. Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, et al. Cancer statistics: breast cancer in situ. CA Cancer J Clin. 2015;65(6):481–95. 10.3322/caac.21321 DOI:
  2. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96(12):906–20. 10.1093/jnci/djh164 DOI:
  3. Groen EJ, Elshof LE, Visser LL, Emiel JT, Winter-Warnars HA, Lips EH, et al. Finding the balance between over-and un-der-treatment of ductal carcinoma in situ (DCIS). Breast. 2017;31:274–83. 10.1016/j.breast.2016.09.001 DOI:
  4. Karavasiloglou N, Matthes KL, Berlin C, Limam M, Wanner M, Korol D, et al. Increasing trends in in situ breast cancer incidence in a region with no population-based mammographic screening program: results from Zurich, Switzerland 2003-2014. J Cancer Res Clin Oncol. 2019 Mar;145(3):653–60. 10.1007/s00432-018-2822-2 DOI:
  5. Bordoni A, Probst-Hensch N, Mazzucchelli L, Spitale A. Assessment of breast cancer opportunistic screening by clinical–pathological indicators: a population-based study. Br J Cancer. 2009;101(11):1925–31. 10.1038/sj.bjc.6605378 DOI:
  6. Virnig BA, Tuttle TM, Shamliyan T, Kane RL, Outcomes JN. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment. J Natl Cancer Inst. 2010;102(3):170–8. 10.1093/jnci/djp482 DOI:
  7. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 2011;129(3):929–38. 10.1007/s10549-011-1531-1 DOI:
  8. Franceschi S, Levi F, La Vecchia C, Randimbison L, Te VC. Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998;77(3):392–5. 10.1002/(SICI)1097-0215(19980729)77:3<392::AID-IJC14>3.0.CO;2-A DOI:<392::AID-IJC14>3.0.CO;2-A
  9. Levi F, Randimbison L, Te VC, La Vecchia C. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer. 2005;116(5):820–3. 10.1002/ijc.20870 DOI:
  10. Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, et al. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality-a population-based study from Sweden. Breast Cancer Res. 2016;18(1):105. 10.1186/s13058-016-0764-7 DOI:
  11. Soerjomataram I, Louwman WJ, van der Sangen MJ, Roumen RM, Coebergh JW. Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer. 2006;95(3):393–7. 10.1038/sj.bjc.6603231 DOI:
  12. Karavasiloglou N, Matthes KL, Pestoni G, Limam M, Korol D, Wanner M, et al. Risk for Invasive Cancers in Women With Breast Cancer In Situ: Results From a Population Not Covered by Organized Mammographic Screening. Front Oncol. 2021 Mar;11:606747. 10.3389/fonc.2021.606747 DOI:
  13. Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without ra-diotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9. 10.1200/JCO.2013.49.5077 DOI:
  14. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102(20):1584–98. 10.1093/jnci/djq366 DOI:
  15. Romero L, Klein L, Ye W, Holmes D, Soni R, Silberman H, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004;188(4):371–6. 10.1016/j.amjsurg.2004.06.034 DOI:
  16. Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, et al. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. J Epidemiol. 2016;26(4):191–8. 10.2188/jea.JE20150010 DOI:
  17. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol. 2010;39(2):598–610. 10.1093/ije/dyp392 DOI:
  18. Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129(12):1020–6. 10.7326/0003-4819-129-12-199812150-00005 DOI:
  19. Modelmog D, Rahlenbeck S, Trichopoulos D. Accuracy of death certificates: a population-based, complete-coverage, one-year autopsy study in East Germany. Cancer Causes Control. 1992;3(6):541–6. 10.1007/BF00052751 DOI:
  20. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161(2):277–84. 10.1001/archinte.161.2.277 DOI:
  21. Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68(1):113–20. 10.1111/j.1541-0420.2011.01640.x DOI:
  22. James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjønneland A, et al. Postmenopausal serum sex steroids and risk of hormone receptor–positive and-negative breast cancer: a nested case–control study. Cancer Prev Res (Phila). 2011;4(10):1626–35. 10.1158/1940-6207.CAPR-11-0090 DOI:
  23. Perme MP, Pavlic K. Nonparametric relative survival analysis with the R package relsurv. J Stat Softw. 2018;87(1):1–27. 10.18637/jss.v087.i08 DOI:
  24. Nagamine CM, de Goulart BN, Ziegelmann PK. Net Survival in Survival Analyses for Patients with Cancer: A Scoping Review. Cancers (Basel). 2022;14(14):3304. 10.3390/cancers14143304 DOI:
  25. Elshof LE, Schmidt MK, Emiel JT, Rutgers FE, Wesseling J, Schaapveld M. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. Ann Surg. 2018;267(5):952–8. 10.1097/SLA.0000000000002239 DOI:
  26. Wärnberg F, Bergh J, Holmberg L. Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. Cancer Epidemiol Biomarkers Prev. 1999;8(9):769–74.
  27. Sopik V, Nofech-Mozes S, Sun P, Narod SA. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat. 2016;155(1):175–85. 10.1007/s10549-015-3666-y DOI:
  28. Yun KW, Kim J, Lee JW, Lee SB, Kim HJ, Chung IY, et al. Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery. J Breast Dis. 2019;7(2):73–80. 10.14449/jbd.2019.7.2.73 DOI:
  29. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888–96. 10.1001/jamaoncol.2015.2510 DOI:
  30. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88. 10.1093/jnci/djr027 DOI:
  31. Matthes KL, Limam M, Dehler S, Korol D, Rohrmann S. Primary treatment choice over time and relative survival of prostate cancer patients: influence of age, grade, and stage. Oncol Res Treat. 2017;40(9):484–9. 10.1159/000477096 DOI:
  32. Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat. 2010;124(2):487–95. 10.1007/s10549-010-0869-0 DOI:
  33. Wanner M, Matthes KL, Korol D, Dehler S, Rohrmann S. Indicators of Data Quality at the Cancer Registry Zurich and Zug in Switzerland. BioMed Res Int. 2018;2018:7656197. 10.1155/2018/7656197 DOI:

Most read articles by the same author(s)